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           In the biotechnology industry, oxidative carbonylation as a post-translational modification 
of protein pharmaceuticals has not been studied in detail. Using Quality by Design (QbD) 
principles, understanding the impact of oxidative carbonylation on product quality of protein 
pharmaceuticals, particularly from a site-specific perspective, is critical. However, 
comprehensive identification of carbonylation sites has so far remained a very difficult analytical 
challenge for the industry. In this work, for the first time the identification of specific 
carbonylation sites on recombinant monoclonal antibodies was reported using a new analytical 
approach via  derivatization with Girard's Reagent T (GRT) and subsequent peptide mapping 
with high-resolution mass spectrometry. Enhanced ionization efficiency and high quality MS
2
 
data resulted from GRT derivatization were observed as key benefits of this approach, which 
enabled direct identification of carbonylation sites without any fractionation or affinity 
enrichment steps. A simple data filtering process was also incorporated to significantly reduce 
false positive assignments. Sensitivity and efficiency of this approach were demonstrated by 
identification of carbonylation sites on both unstressed and oxidized antibody bulk drug 
substances. The applicability of this approach was further demonstrated by identification of 14 
common carbonylation sites on three highly similar IgG1s. This approach represents a significant 
improvement to the existing analytical methodologies and facilitates extended characterization of 
oxidative carbonylation on recombinant monoclonal antibodies and potentially other protein 
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INTRODUCTION     
       Recombinant monoclonal antibodies (mAbs) are an important class of biotherapeutics, 
with more than 30 mAb drug products approved for various indications and hundreds in clinical 
trials.
(1)
 Recently, a Quality-by-Design (QbD) paradigm was introduced by the US Food and 
Drug Administration (FDA) for the pharmaceutical development of biologics.
(2)
 A key part of the 
QbD approach is establishing critical quality attributes (CQAs) to help in designing control 
strategies, setting specifications, and defining a proper manufacturing space.
(2)
 For mAb drug 







 Given the heterogeneous nature of mAbs, characterization of various mAb 
product variants has proven to be a challenging task.
(6),(7),(8) 
In a recent review article, Beck et al. 
provided a comprehensive summary of the current state of the art in characterizing a wide range 
of mAb variants,
(9)
 which illustrates the complexity of mAb molecules and highlights the 
tremendous analytical efforts required. Moreover, new mAb variants are expected to be 
discovered in the coming years, further contributing to the already complex landscape of mAb 
characterization.  
             In biological systems, protein carbonyls can be formed through the α-amidation pathway 
during oxidative cleavage of the protein backbone, by Michael addition reaction with --
unsaturated aldehydes, during glycation and glycoxidation processes, and by metal catalyzed 
oxidation (MCO).
 (10-14)
 Specifically, for oxidative carbonylation by MCO, side chains of amino 
acids are attacked by free radicals, such as hydroxyl radicals (
.
OH) generated from reactions 
catalyzed by metal ions, which result in the formation of glutamic semialdehyde from arginine 
and proline residues, aminoadipic semialdehyde from lysine residue, and 2-amino-3-ketobutyric 
acid from threonine residue (Figure 1).
(15, 16)




Alzheimer’s diseases, diabetes, and chronic renal failure, these various types of protein 
carbonylation have attracted significant interest from the medical research community.
(10),(12)
 
Additionally, due to its irreversible and unrepairable nature, protein carbonylation is widely 
adopted as a biomarker to study oxidative stress in biological systems.
(13),(14),(17),(18),(19)
  
             In the biotechnology industry, oxidative carbonylation by metal catalyzed oxidation 
could be particularly relevant since metals are present throughout the manufacturing process.
(20, 
21),(22),(23) 
For protein pharmaceuticals, oxidative carbonylation, as a post-translational 
modification, could have a significant effect on protein physicochemical properties. For example, 
arginine and lysine carbonylation leads to loss of the positive charge on the respective side 
chains and increase of the molecule hydrophobicity. Proline carbonylation leads to loss of the 
steric constraint, an important protein stabilizing force. Furthermore, aldehyde groups resulting 
from oxidative carbonylation can react with adjacent lysine residues to form a Schiff base, 
generating intra- or inter- molecule cross-links. These changes in turn can cause loss of function 
and/or accumulation of high molecular weight aggregates.
(13),(14)
 Therefore, oxidative 
carbonylation potentially presents a risk to product quality, and should be carefully investigated. 
However, to date, there have been very few reports investigating oxidative carbonylation in this 
context. Steinmann et al. reported 0.25 mole of protein carbonyls per mole of protein in oxidized 
human growth hormone.
(24)
 Bee et al. reported a fourfold increase of protein carbonylation to 0.8 
mole of carbonyl per mole of mAb in the aggregates absorbed on a stainless steel surface 
compared to a control mAb sample and proposed that Fe ions leached from the steel were a 
likely cause for the oxidative carbonylation in their case.
(23)
               


















Figure 1. Structures of the oxidative carbonylation products of Arginine, Threonine, Proline, 







          A critical factor to consider during mAb product quality assessment is immunogenicity, 
which refers to the ability of the antigen (mAb drug products) to induce the immune responses. 
The induced immune responses against a mAb product can lead to reduced efficacy of the 
product and/or cause safety issues such as anaphylaxis.
(25)
 In general, there are two types of the 
immune responses: the adaptive immunity, which is long lasting and specific, and the non-
adaptive immunity, which is generic and does not have high specificity.
(26)
 For the 
immunogenicity of mAb products, both types of the immune responses may be involved, and the 
mechanism is quite complex. For example, one route is through stimulation of antigen presenting 
cells (including the dendritic cells and some B cells) without requiring co-stimulation of the 
CD4+ helper T cells,
(27)
 while another route is T-cell dependent.
(27)
 In addition, for antigens such 
as virus coat proteins or aggregates with ordered protein structures or regular repeating pattern, 




             Due to the complex nature of immunogenicity, it is often difficult to evaluate the 
immunogenicity risk for a monoclonal antibody product candidate.
(28)
 For example, 
immunogenicity has been observed for even fully humanized recombinant monoclonal antibody 
products.
(29)
 Furthermore, a wide range of immunogenicity profiles have been observed in the 
FDA approved antibody therapeutics, with the observed frequency ranging from 0% in 
Bevacizumab (Avastin) patients to 44% in Abciximab (Reopro) patients.
(26)
 Many factors, such 
as protein sequence, structural framework, and physiochemical characteristic of the mAb 
molecule, may contribute to the immunogenicity. While protein sequence and structural 




physiochemical characteristic of a mAb product may vary due to variation or changes in the 
manufacturing process. It is therefore important to perform extensive physiochemical 
characterization to help evaluate the immunogenicity during mAb product development. As a 
product quality attribute for the physiochemical characterization, oxidative carbonylation has not 
been specifically evaluated for its impact on immunogenicity for mAbs. However, existing 
reports in the literature suggest a link between immunogenicity and various types of 
carbonylation products, particularly in the autoimmune diseases.
(30)
 For example, Kirkham et al. 
showed a correlation between the intensity of immune response (reflected by the observed titer 
of the induced antibody against carbonyl-modified endogenous proteins) and the level of 
carbonyls in blood and peripheral lung, in both chronic obstructive pulmonary disease patients 
and ozone-exposed mice.
(31)
 This study supports that the oxidation stress can trigger immune 
responses against the carbonylated endogenous proteins.
(31)
 In another study, Allison and Fearon 
demonstrated that a non-immunogenic protein, merozoite surface protein-1, can be effectively 
converted to an immunogenic antigen by attaching a glycol-aldehyde tag to the protein in mouse 
model, where the induced immunogenicity was specifically attributed to the aldehyde moiety.
(32)
 
Recently, Filipe et al. compared the immunogenicity of mAb samples stressed under different 
conditions, such as pH shifts, shaking, heating, and metal-catalyzed oxidation, in transgenic and 
non-transgenic mouse models.
(33)
 Interestingly, the mAb aggregates from the metal-catalyzed 
oxidation were found to be significantly more immunogenic than the aggregates generated from 
the other stress conditions.
(33)
 The oxidative carbonylation products, among other oxidation 
products, were considered a higher immunogenicity risk than other aggregate features.
(33)
   
                Given the potential impact to mAb’s efficacy, stability, and immunogenicity, oxidative 




level, oxidative carbonylation can be quantified by a number of assays.
(34),(35)
 One of the most 
commonly used assays employs 2,4-dinitrophenyhydrazine (DNPH) as a derivatization reagent. 
The resulting hydrazone has a strong absorbance at 375 nm, which is the basis for quantitation 
by UV absorbance spectroscopy of this assay.
(35)
  At the peptide level, identifying and 
characterizing oxidation carbonylation sites on proteins is particularly challenging.
(36)
 A number 
of factors contribute to the difficulty. First, carbonylation is normally distributed on multiple 
sites at low levels.
(37),(38)
 Second, loss of positive charges from lysine and arginine can reduce 
ionization efficiency and impair detection sensitivity for mass spectrometry analysis. Third, 
aldehyde groups may react with primary amines during peptide mapping and the sample 
digestion process, which obscures subsequent analysis. Therefore, chemical derivatization is 
necessary to protect the carbonyl groups before peptide mapping. Mirzaei and Regnier reported a 
method using biotin hydrazide as a derivatization reagent to form a hydrazone with protein 
carbonyl groups, which allows selective enrichment of the biotinylated proteins by avidin 
affinity chromatography for subsequent tryptic peptide mapping.
(39)
 Applying the biotin 
hydrazide method, Madian and Regnier identified carbonylated proteins in human plasma;
(40)
 
Madian et al. evaluated the effects of antioxidants on carbonylation;
(41)
 Temple et al. identified 
carbonylation sites on oxidized human serum albumin.
(42)
 Using a similar analytical strategy, 
Chavez et al. used aldehyde reactive probe (ARP), N’-aminooxymethylcarbonyl hydrazine-D-
biotin, for derivatization and affinity capture of carbonylated proteins and identified 
carbonylation sites on oxidized glyceraldehyde-3-phosphate dehydrogenase and on some 
mitochondrial proteins.
(43)
 In another report, Mirzaei and Regnier described the method using 
Girard’s P reagent (GRP) for derivatization and strong cation exchange chromatography for 
enrichment of GRP-peptides after proteolysis.
(11)




derived peptides have increased ionization efficiency with the introduced pyridinium moiety 
from GRP. Finally, Lee et al. reported a method using a custom-synthesized affinity tag for 
identification and quantitation of carbonylation sites on human serum albumin.
(44)
  
            For biotechnology products, the location of oxidative carbonylation sites on monoclonal 
antibody drugs will be essential for proper assessment of the impact of this modification on drug 
product quality. However, site-specific characterization of oxidative carbonylation on therapeutic 
proteins has yet to be reported. An issue with the current analytical methodologies is that high-
yield recovery of chemically labeled oxidatively carbonylated peptides/proteins from affinity 
capture or strong cation exchange chromatography can be difficult to achieve, which may lead to 
missed identification of important carbonylation sites on biotherapeutic proteins. Another issue is 
that some of the chemical tags can interfere with the peptide fragmentation pattern during LC-
MS/MS analysis,
(11),(45)
 making data interpretation and site identification difficult. 
In this work, a novel analytical method for characterizing oxidative carbonylation on 
recombinant monoclonal antibodies was reported. Girard Reagent T, a reagent originally used for 




 is employed for derivatization of the carbonyl 
groups on mAbs. Like GRP, Girard Reagent T has a quaternary ammonium moiety which adds a 
positive charge to the derived peptides for increased ionization efficiency. After derivatization, 
mAb samples are directly analyzed by peptide mapping without enrichment or fractionation. The 
high quality of MS/MS spectra of GRT derived peptides allows pinpointing the exact 
carbonylation sites on mAbs with high confidence by the Proteome Discoverer database search 
engine. The sensitivity and effectiveness of this method are demonstrated by detecting and 
identifying multiple carbonylation sites on an unstressed IgG1 bulk drug substance as well as on 




existing analytical methodologies for characterization of oxidative carbonylation on protein 
pharmaceuticals and should be readily applicable for characterization of oxidized proteins in 
other biological systems.                  
EXPERIMENTAL SECTION 
               Materials. IgG1A, IgG1B, and IgG1C were manufactured at Genentech (South San 
Francisco, CA).  (Carboxymethyl)trimethylammonium chloride hydrazide (Girard’s Reagent T, 
GRT), dithiothreitol (DTT), iodoacetic acid (IAA), ferrous sulfate, hydrogen peroxide solution 
(30% in H2O, w/w), methionine (Met), ethylenediaminetetraacetic acid (EDTA), calcium 
chloride, tris(hydroxymethyl) aminomethane (Tris), sodium acetate, acetic acid, sodium 
hydroxide solution (1M in H2O), and thermolysin from Bacillus were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Trifluoroacetic acid (TFA), guanidine hydrochloride, tris(2-
carboxyethyl) phosphine HCl (TCEP), and BCA protein assay kit were purchased from Thermo 
Fisher Scientific (Rockford, IL, USA). Acetonitrile (ACN) was purchased from Burdick & 
Jackson (Muskegon, MI, USA). OxiSelect
TM 
 protein carbonyl spectrophotometric assay kit was 
purchased from Cell Biolabs (San Diego, CA, USA). Sequencing-grade trypsin was purchased 
from Promega (Madison, WI, USA).  
              Methods. Oxidation of mAbs. Antibody samples were subjected to metal catalyzed 
oxidation. For the oxidation reaction, each antibody sample (5 mg/mL final concentration) was 
mixed with FeSO4 (2 mM final concentration) and hydrogen peroxide (10 mM final 
concentration) in a 50 mM sodium succinate buffer, pH 6.5. The reaction mixture was incubated 
at room temperature for 16 hours for high level oxidation or for 2 hours for medium level 




methionine and EDTA to quench residual hydrogen peroxide and free Fe ions in the reaction 
mixture.   
               Determination of Protein Carbonyl Levels of mAbs. Protein carbonylation levels for the 
unstressed and oxidized IgG1A mAb samples were measured using the OxiSelect
TM
 Protein 
Carbonyl Spectrophotometric Assay Kit (Cell Biolabs, Inc., San Diego, CA) following the 
procedure recommended by the manufacturer. For each sample, three independent measurements 
were performed. An average value of the protein carbonyl levels from the three independent 
measurements was then reported for each sample. 
               Derivatization of mAb samples with GRT. The mAb samples, 16-hour oxidized IgG1A, 
IgG1B, IgG1C, 2-hour oxidized IgG1A, and unstressed IgG1A, were buffer exchanged into 50 
mM sodium acetate buffer, pH 4.5, using Amicon Ultra-15 30 KDa filter units (Millipore, 
Billerica, MA, USA) to a final protein concentration of 5 mg/mL. The buffer-exchanged mAb 
samples were then subjected to the GRT labeling reaction. To each sample, GRT was added to a 
final mAb-to-GRT molar ratio of 1:10,000. After brief mixing, the reaction mixture was 
incubated at room temperature for 16 hours in the dark. The derivatization reaction was then 
stopped by freezing at -80 °C. An aliquot of each GRT-derivatized sample was subsequently 
buffer exchanged into 25 mM sodium phosphate buffer, pH 6.5 using Amicon Ultra-15 30 kDa 
filter units.            
             Sodium Borohydride Reduction. GRT-derivatized mAb samples were reduced by sodium 
borohydride, according to a protocol described by Brady et al.
(48)
 Sodium borohydride solution 
(100 mM) was prepared fresh in 0.02 M NaOH immediately before its use. An aliquot of 200 µL 
GRT-derivatized mAb sample (10 mg/mL) was mixed with 160 µL of 400 mM sodium 




mixture was incubated at room temperature for 1 hour. Subsequently, GRT-derivatized sodium 
borohydride-reduced mAb samples were buffer exchanged into 25 mM sodium phosphate buffer, 
pH 6.5 using Amicon Ultra-15 30 kDa filter units.           
             Molecular Mass Analysis of GRT-derivatized Sodium Borohydride-reduced and TCEP-
reduced IgG1A. The GRT-derivatized and sodium borohydride-reduced IgG1A samples (2 
mg/mL) were mixed with the TCEP solution (5 mg/ml in H2O) at 1:1 (volume to volume) ratio. 
The mixture was incubated at 55 °C for 15 minutes. After incubation, the mixture was cooled to 
room temperature and diluted with water to a final protein concentration of 0.05 mg/mL and 
stored at 2-8 °C for subsequent mass analysis.  Molecular mass analyses of TCEP-reduced 
IgG1A samples were carried out on an Agilent 6210 electrospray ionization time-of-flight mass 
spectrometer (Agilent, Santa Clara, CA). Desalting and separation of the GRT-derivatized 
Sodium Borohydride-reduced and TCEP-reduced IgG1A samples were performed using an 
Agilent custom order chip packed with Zorbax 300SB-C8 5µm stationary phase. A linear 
gradient of 10% to 60% B in 6 minutes at a flow rate of 0.4 µL/min was employed, where mobile 
phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in acetonitrile. 
Approximately 5 ng of the IgG1A material was injected for analysis.  The acquired mass spectra 
were then deconvoluted with the Agilent MassHunter software.      
             Trypsin and Thermolysin Digestion. GRT-derivatized mAb samples (with and without 
sodium borohydride reduction) were digested by trypsin and thermolysin. Before enzymatic 
digestion, the mAb samples were denatured, reduced, and alkylated (S-carboxymethylation) as 
previously described.
(7)
 Reduced and alkylated mAb samples were then buffer exchanged into a 
digestion buffer (25 mM Tris-HCl, 1 mM CaCl2, pH 8.2) using a Sephadex G-25M PD-10 




were digested with an enzyme-to-substrate ratio of 1:50 (weight to weight) at 37 °C for 5 hours 
and the digestion was stopped by addition of TFA to a final concentration of 0.3%. For 
thermolysin digestion, the samples were digested with an enzyme-to-substrate ratio of 1:100 
(weight to weight) at 50 °C for 30 minutes, and stopped by addition of EDTA to a final 
concentration of 3.75 mM. The trypsin and thermolysin digests were then stored at 2-8 °C prior 
to subsequent analysis.     
              LC/ESI-MS/MS Analysis and Proteome Discover Database Search. Trypsin and 
thermolysin digested mAb samples were analyzed by LC/ESI-MS/MS with an Agilent 1200 
HPLC system connected to a Thermo Scientific LTQ OrbiTrap Velos mass spectrometer (San 
Jose, CA). The digested peptides (35 ug per injection) were separated on an Eclipse XDB-C8 
column (2.1x150 mm, 3.5 um). Mobile phase A was 0.1% TFA in water. Mobile phase B was 
0.09% TFA in 90% acetonitrile and 10% water (v/v). The peptides were eluted from the column 
with a step gradient as follows: 0-10% B in 20 minutes and then 10-40% B in 137 minutes, with 
a flow rate of 0.25 ml/min. Column temperature was controlled at 55 °C. The eluted peptides 
were analyzed by the OrbiTrap mass spectrometer in the positive ion mode. The electrospray 
voltage was 4.0 kV. The capillary temperature was 270 °C.  The MS data were acquired in a data 
dependent mode, where a full MS survey scan was followed by MS/MS scans of the 9 most 
intense ions. The full MS data (m/z 300 to m/z 2000) were acquired in the Orbitrap mass 
analyzer with a resolution of 60,000.  The MS/MS data were acquired in the LTQ by collision 
induced dissociation, with the normalized collision energy of 35 and the activation time of 10 
milliseconds.  
The acquired mass spectral data were searched against a custom created database 




using the SEQUEST (V1.20) algorithm. The monoisotopic masses of the  modifications  of GRT 
derivatized (and sodium borohydride-reduced) oxidation products of Lys, Arg, Pro, and Thr were 
manually calculated as shown in Table 1, and were selected as dynamic modifications during the 
search. Other database search parameters were as follows: precursor mass tolerance of 5 ppm, 
MS/MS mass tolerance of 0.8 Da, and a fixed modification of carboxymethylation on cysteine.  
For the trypsin digest, the enzyme specificity was set as full with maximum of two missed 
cleavages. For the thermolysin digest, the enzyme specificity was set as none. The same database 
searching parameters as listed above were applied to the samples not treated with sodium 
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RESULTS and DISCUSSION 
             Analytical Strategy for Extended Characterization of Oxidative Carbonylation on 
Monoclonal Antibodies. To develop an analytical strategy for extended characterization of 
monoclonal antibodies, a derivatization strategy that allows direct detection and identification of 
carbonylated peptides during LC-MS/MS peptide mapping was explored. Specifically, hydrazide 
reagents that provide enhanced ionization efficiency for MS analysis, and that yield no or little 
self-fragmentation during collision induced dissociation (CID) experiments are preferred. 




 Girard’s Reagent T (GRT, 
Figure 2), was considered as the derivatization reagent for this study based on the following 
features. First, GRT carries a positively charged quaternary ammonium group and has a very 
high solubility in water. The ionization efficiency of GRT-derivatized peptides should be 
enhanced because of the positive charge introduced after derivatization and the improved 
solubility of the resulting peptides. Second, based on the small size and relatively simple 
chemical structure of GRT, it was speculated that GRT-tagged peptides should be less prone to 
tag self-fragmentation during the CID experiment than with other more complex hydrazide tags 
such as ARP.
(43)
 Third, also because of the small molecular size of GRT, more carbonylation 
sites may be accessible to GRT than to other bulkier hydrazide reagents. In addition, it is worth 
noting that compared to a similar hydrazide reagent GRP,
(11)
 GRT has a higher solubility in 
water,
(49)
 which allows higher reagent-to-protein molar ratio for derivatization (given the same 
protein concentration), and a smaller molecular weight, which potentially provides slightly better 
site accessibility. Based on these additional considerations, GRT was finally selected as the 
derivatization reagent in this study.   














Figure 2. Structure of GRT and the derivatization reaction of GRT with oxidized proteins 
(showing oxidized arginine residue as an example) to form hydrazone products where the Schiff 






           Metal Catalyzed Oxidative Carbonylation of Monoclonal Antibodies. In this study, 
three full-length IgG1 mAb molecules produced at Genentech were used as model mAbs to 
investigate oxidative carbonylation. Several factors were considered when selecting industry-
relevant stress conditions to generate oxidative carbonylation on the model mAbs. First, among 
the various metal catalyzed oxidation systems described by Stadtman,
(50)
 the Fe(II)/H2O2 system 
is considered more pharmaceutically relevant since both Fe(III) and H2O2 may be commonly 
present during mAb manufacturing and storage processes, and Fe(III) can be converted to Fe(II) 
via reaction with H2O2.
(51)
 Therefore this oxidation system was selected in this study. Second, the 
pH for the oxidation reaction was also considered as a critical factor. At basic and neutral pHs, 
N-terminal amine groups and lysine side chains are increasingly deprotonated and can potentially 
form Schiff bases with aldehyde groups generated during MCO, thus interfering with subsequent 
carbonylation analysis. Acidic pHs are therefore preferred. Considering also the pH range of the 
cell culture environment
(21)
 and the common formulations
(52)
 for mAbs, I selected a pH value of 
6.5 for the MCO reaction. Third, I evaluated various buffer systems for an optimal buffer to 
carry out the oxidation experiment, since interferences with Fe ions or with the oxidation 
reaction from the buffer components may introduce variations to the oxidation reaction, and thus 
should be minimized. Many commonly used buffers are not ideal for the Fe(II)/H2O2  system. For 
example, phosphate ions may form insoluble salts with Fe ions; Tris and citrate can act as Fe ion 
chelators; MES can, in fact, be oxidized by the Fe(II)/H2O2 system (unpublished results). 
Therefore, for this study, sodium succinate buffer was selected for its lack of the solubility and 
chelating issues with Fe ions, and its capability for buffering at pH 6.5. 
       Total protein carbonyl levels of the unstressed and oxidized IgG1A samples were 
determined by the 2,4-dinitrophenylhydrazine (DNPH) colorimetric assay
(35)




manufacturer’s procedure. The carbonylation levels for the unstressed, 2-hour oxidized, and 16-
hour oxidized IgG1A bulk drug substance were 0.05±0.02, 1.3±0.1, and 1.9±0.1 mole of 
carbonyl per mole of mAb, respectively. These results show that, as expected, significant 
oxidative carbonylation of mAbs can indeed be induced through metal catalyzed oxidation 
reactions with the Fe(II)/H2O2 system. At such a high protein carbonyl level, it was suspected 
that oxidative carbonylation could be generated on most if not all potential carbonylation sites on 
IgG1A with the 16-hour oxidation condition. In contrast, for the unstressed IgG1A, its protein 
carbonyl level is even lower than the level reported by Bee et al.
(23)
 on an IgG1 bulk drug 
substance. Therefore the unstressed IgG1A should be a suitable sample to test the sensitivity of 
the analytical method for this study.     
                Optimization of the GRT Derivatization Reaction. For the derivatization reaction, 
the hydrazine group of GRT reacts with carbonyl groups on mAbs to form hydrazones (Figure 2). 
In this study, the derivatization reaction was carried out in 50 mM sodium acetate buffer at pH 
4.5, since hydrazone formation is favored at acidic pHs.
(46)
 The 16-hour oxidized IgG1A sample 
was used as a model mAb sample to optimize the GRT derivatization condition. First, the mAb-
to-GRT molar ratio was optimized by mixing an aliquot of the highly oxidized IgG1A (5 mg/mL 
in the final reaction mixture) with GRT at 1:500, 1:1,000, 1:2,500, 1:5,000, 1:7,500, 1:10,000, 
and 1:12,500 mAb-to-GRT molar ratios. The reaction was carried out for 16 hours at room 
temperature and stopped by freezing at -80 °C. Subsequently, all these samples were treated with 
sodium borohydride to reduce the Schiff base to a more stable hydrazine product for the mass 
analysis, enabling the selection of an optimal derivatization condition based on the relative 




               In the deconvoluted mass spectra of the reduced IgG1A light chain (LC), as shown in 
Figure 3, GRT-derivatized carbonylated species were readily observable. The mass species of 
23399.1 Da is consistent with GRT-derivatized carbonylated products of threonine/lysine of LC. 
The mass species of 23383.9, 23415.4, and 23431.7 Da are likely correspondingly Thr/Lys-
modified LC mass species of 23269.5, 23301.5, 23317.5 Da,  with a consistent mass shift of 
approximately 113-114 Da, respectively. For the heavy chain (HC), the deconvoluted mass 
spectra were much more complicated due to the more heterogeneous nature (variations at C-
terminal lysine and N-glycosylation
(53)
 of the HC. Nevertheless, the trend of intensities of the 
derivatized species of HC with increasing GRT-to-mAb molar ratios was generally consistent 
with that observed for the LC (HC data not shown). To simplify the process for optimizing the 
derivatization reaction, the relative intensity of the LC product with the mass of 23399.1 Da was 
used as a surrogate indicator for the extent of GRT derivatization. As shown in Figure 4 and 
Figure 5 (the raw MS spectra), the mAb-to-GRT molar ratio of 1:10,000 demonstrated an 
optimal derivatization condition, where the derivatization yields reach a plateau (Figures 6A), 
and beyond which there was little increase in the relative intensities of the GRT-derived 
carbonylated species. Similarly, the GRT derivatization reaction time was optimized by 
evaluating the extent of derivatization for 1, 2, 4, 8, 16, and 24 hours with a mAb-to-GRT molar 
ratio of 1:10,000. A reaction time of 16 hours demonstrated an optimal derivatization condition 
(Figure 6B). Therefore the mAb-to-GRT molar ratio of 1:10,000 and the reaction time of 16 
hours were selected as a final GRT derivatization condition for the subsequent studies.  











































Figure 3. Deconvoluted mass spectra of 16-hour oxidized IgG1A light chains derivatized with 
GRT in 0 (control), 500, 1,000, 2,500, 5,000, 7,500, 10,000, and 12,500 molar ratios followed by 























































Figure 4. Expanded view of the deconvoluted mass spectra of 16-hour oxidized IgG1A light 
chains derivatized with GRT in 0 (control), 500, 1,000, 2,500, 5,000, 7,500, 10,000, and 12,500 
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Figure 5. (A) Raw spectra of the reduced light chain of the control sample in the mAb-to-GRT 
molar ratio optimization experiment. (B) Raw spectra of the reduced light chain of the sample 
with a mAb-to-GRT molar ratio of 1:10,000 in the mAb-to-GRT molar ratio optimization 
experiment. (C) Comparison of the raw spectra in an expanded view. GRT derivatization 
resulted in enhanced ionization efficiency for the carbonylation products (predominant ions 
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Figure 6A. Molar ratio optimization of GRT derivatization reaction. Oxidized IgG1A sample 
was mixed with GRT at 0, 500, 1,000, 2,500, 7,500, 10,000, and 12,500 molar ratios and 
incubated at room temperature for 16 hours. The derivatization reaction reached a plateau at 


































Figure 6B. Time course optimization of GRT derivatization reaction. Derivatization mixtures 
(molar ratio 1:10,000 of oxidized IgG1A/GRT) were incubated at room temperature, in the dark 










             It is also interesting to note that the relative intensities for all other observed masses 
remained largely unchanged compared to the intensity of the GRT-derivatized carbonyl species 
in the mass spectra of reduced IgG1A (Figure 3), which suggests that without GRT 
derivatization the carbonylated products are either undetectable or present at very low intensities. 
This observation is consistent with the expectation that derivatization with GRT can enhance 
ionization efficiency of carbonylated species of mAbs because of the introduced permanent 
positive charge, thus improving the sensitivity for detecting carbonylation on mAbs.     
               Proteolysis and LC-MS/MS. For extended characterization of carbonylation sites on 
mAbs, I carefully considered a proteolysis strategy and LC-MS/MS settings to maximize the 
success rate of positive identification of carbonylation sites. First, for proteolysis, both trypsin 
and thermolysin
(54)
 digestions were employed, which in combination achieved 100% sequence 
coverage for all three IgG1s. An additional consideration for using both trypsin and thermolysin 
is that lysine and arginine carbonylation sites are uncleavable by trypsin; therefore, the resulting 
tryptic peptides can be very large. As a consequence, the quality of the MS/MS spectra of these 
large tryptic peptides may be very poor, making identification by database searching difficult. 
Thermolysin, on the other hand, while not as specific as trypsin, may produce several smaller-
sized peptides covering the modified lysine and arginine sites, thereby facilitating identification. 
Second, for the HPLC condition, to address the concern of the permanent positive charge of 
GRT on derivatized peptides engaging in a potential strong ionic interaction with surface silanol 
groups on a silica based reverse phase column,
(55)
 a reverse phase column with an end-capped 
stationary phase was chosen. Third, for MS/MS data acquisition, the collision induced 




spectrometer in this mode, which allows more low-abundant ions to be selected for 
fragmentation.  
              Identification of Carbonylation Sites on Oxidized and Unstressed IgG1A. 
Identification of carbonylation sites on IgG1A samples was achieved through database search of 
the MS
2
 data acquired from peptide mapping. It should be noted that MCO can generate a large 
variety of modifications besides carbonylation on proteins.
(15, 50)
 Therefore, false positives may 
be present in database search results. Additionally, artifacts from enzymatic digestion, such as 
missed or non-specific cleavages, could also contribute to false positive identification of 
carbonylation sites. In some cases, these false positives could also have high quality MS
2
 data, 
making them difficult to rule out. Clearly, these issues pose some serious challenges for high-
confidence assignment of carbonylation sites on proteins. Surprisingly, there have been very few 
publications that employed specific strategies to address these false positive issues. In one case, 
the false positive issues were observed by Mirzaei and Regnier and addressed in their work 
through the use of stable isotope labeled GRP 
(56)
 in a multiplexing fashion.  
               In this work, a filtering process as illustrated in Figure 7 was employed to reduce false 
positive identifications. This simple data filtering process was found to be highly effective in 
reducing false positives. In this process, one aliquot of a GRT-derived mAb sample was reduced 
by NaBH4 and the other aliquot was not. Subsequently, these two aliquots were subjected to 
identical peptide mapping and database search processes. After the database search, two lists, A 
and B, containing identified carbonylation sites from the aliquots with NaBH4 reduction and 
without NaBH4 reduction, respectively, were generated. Given that the customized modification 
masses (Table 1) used for database search were calculated including the two additional hydrogen 




positives. Therefore, a carbonylated peptide hit identified in list A can be ruled out as a false 
positive if this same peptide hit is also identified in list B. As an example to demonstrate the 
effectiveness of the filtering process, from thermolysin mapping of a 16-hour oxidized IgG1A 
sample, list A contained 127 peptide hits while list B contained 83 peptides hits. When list A was 
compared with list B, 67 common peptide hits were found on both lists. These 67 peptide hits 







































               After the false positives were removed through the filtering process, the remaining MS
2
 
spectra were further investigate with high-confidence database search scores for positive 
identification of carbonylation sites. Shown in Figure 8 is an example of collision-induced 
dissociation (CID) MS
2
 spectra for a positively identified carbonylation site of Arg18 on the light 
chain of IgG1A.  Figure 8 illustrates the MS
2 
spectrum of a doubly charged GRT-derivatized 
peptide ion with m/z of 538.80139, corresponding to amino acids 11-20 on the light chain of 
IgG1A, while the MS
2 
spectrum of the doubly charged parent peptide ion with m/z of 502.77255 
is shown in the Figure 9. In both MS
2 
spectra, a continuous b ion series of b7, b8, and b9, 
covering the Arg18 site was observed, which allowed us to pinpoint the carbonylation site at 
Arg18.  Additionally, the y ions (y4 to y8) in Figure 8 are consistent with GRT derivatization of 
carbonylated Arg18 of this peptide. More significantly, in Figure 8, b9
2+
 became a predominant 
fragment ion. This unique intensity profile is consistent with a positive charge introduced by 
GRT derivatization into the original carbonyl product derived from Arg18. Overall, the high 
quality MS
2
 data in this example provided an unambiguous assignment of R18 as a carbonylation 
site on IgG1A.   
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Figure 8. CID MS/MS spectrum of a GRT derivatized carbonylated peptide. R highlighted in red 
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           As discussed earlier, hydrazide tag-specific fragmentation during CID experiments can be 
a  challenge for identification of carbonylation sites by database search.
(36)
 In most of the cases, 
GRT self-fragmentation in the MS
2
 spectra was not observed. Occasionally, however, GRT self-
fragmentation was observed. As an example, the ion with m/z 1017.6 in Figure 8 is a singly 
charged ion resulting from GRT self-fragmentation, losing the positively charged ammonium 
moiety, HN
+
 (CH3)3, from the doubly charged GRT-derivatized peptide ion with m/z 538.80139. 
It is interesting that the GRT self-fragmentation in this case has not affected the database search 
for the identification of carbonylation sites. This benign effect was likely due to the relatively 
simple GRT self-fragmentation pattern, as also illustrated in the work on GRT derivatization of a 
nucleoside,
(46)
 which does not cause the resulting MS
2
 spectra to be overly complex. In fact, 
when the GRT self-fragmentation occurs, the characteristic loss of the ammonium moiety from 
GRT in the MS
2
 spectra can be considered as additional evidence to support positive 













             A total of 30 carbonylation sites were identified on the 16-hour oxidized IgG1A, as 
shown in Table 2. Identification of each of these carbonylation sites passed the four criteria: 1. 
precursor ion is within 5 ppm of the theoretical mass; 2. identified peptides are present only in 
the NaBH4 reduced maps (one example shown in Figure 10); 3. database search result is of a 
high-confidence database search score (Xcorr scores greater than 1.8, 2.3, 3.0, 3.5, for the charge 
state of 1, 2, 3, 4, respectively); 4. site assignment is further verified by manual investigation of 
the data. In some cases, carbonylation sites were confirmed on both trypsin and thermolysin 
maps or from multiple peptides on the thermolysin map, which provided additional support for 
positive site assignment. It is also interesting to note that threonine was found to be the most 
frequently oxidized residue on the LC, which is consistent with the deconvoluted light chain 
mass spectra as shown in Figure 4. Since lysine carbonylation in IgG1A LC was not observed, 
the 23399.1 mass in Figure 4 likely results from predominantly threonine carbonylation on the 
LC.  














IgG1 A  IgG1 B  IgG1 C  
LC T5Th Tr, R18Th, R24Th, T69Th,  
T74Th,  
P80Th Tr, T85Th Tr, T97Th, T109Tr,  
T164Th Tr, T172Th, T180Tr, 
P204Tr, T206Tr 
T5Th Tr, P8Th Tr, R18Th, 
R24Th, R66Th, P80Th Tr, 
T109Tr, P113Tr, P141Tr, 
T164Tr, T180Th, P204Tr, 
T206Tr 
T5Th Tr, R18Th, T20Tr, 
T22Th, T69Th Tr, P80Th Tr, 
T109Tr, T164Th, P204Tr, 
T206Tr 
HC R19Th, T30Th Tr,  
T57Th Tr, T98Tr, T114Th, T120Th, 
T135Tr,T155Th Tr, K205Th, 
K214Th, T225Th Tr, T256Tr, 
P271Tr, K290Th, P329Tr, T394Tr 
R19Th, T74Th Tr, K76Th, 
T123Tr, T138Tr, T158Th, 
T167Th, P192Th, T198Th, 
R258Th, T259Th Tr, 
K293Th, P332Th Tr, P377Tr, 
T396Th, P398Tr 
R19Th, T74Th Tr, T126Th, 
T141Tr, T161Th, T170Th, 
T262Th Tr, P277Tr, 
K296Th,  
P335Th Tr,  
P393Th Tr  
 
Table 2. Carbonylation sites identified on the 16-hour oxidized IgG1A, IgG1B, and IgG1C 
(common carbonylation sites are underlined and in bold; Th: identified on a Thermolysin map; 















c:\documents and settings\...\1c 11/1/2012 3:11:28 AM
RT: 33.52 - 34.92






























































































1#6102  RT: 
34.28  AV: 1 F: 






1c#6035  RT: 
34.29  AV: 1 F: 

























EIC of m/z 538.80139 on
thermolysin map of
16-hour oxidized IgG1A 
+ GRT
with NaBH4 treatment
EIC of m/z 538.80139 on
thermolysin map of







Figure 10. Extracted ion chromatograms (EIC), targeting the NaBH4-reduced GRT derivatized 
carbonylated R18 peptide (a doubly charged ion of m/z of 538.8013), of the thermolysin maps 
from the two 16-hour oxidized IgG1A aliquots (the aliquot with NaBH4 reduction was shown in 
the upper panel; the other aliquot without NaBH4 reduction was shown in the lower panel). 
Absence of the doubly charged ion of m/z of 538.8013 in the EIC of the aliquot not reduced with 
NaBH4 (the lower panel) is consistent with positive assignment of R18 as a carbonylation site on 







      To demonstrate the sensitivity, this approach was applied to the unstressed and 2-hour 
oxidized (using the Fe(II)/H2O2 system) IgG1A, which identified 22 sites on the 2-hour oxidized 
and 9 sites on the unstressed IgG1A, respectively (Table 3). Identification of the 9 carbonylation 
sites on the unstressed IgG1A is particularly satisfying as it demonstrates the sensitivity of the 
method for the identification of site-specific carbonylation on an mAb sample with low protein 
carbonylation levels without using any affinity or fractionation steps. In addition, this analytical 
approach was compared with a previously described regular peptide mapping method 
(7)
 without 
GRT derivatization for characterization of oxidative carbonylation. It was found that none of the 
oxidative carbonylated peptides could be identified on the regular peptide maps of both the 
unstressed and the 16-hour oxidized IgG1A samples (Figure 11A to 11D), which further 




















Identified in 2-hr 
oxidized IgG1A 
Identified in 16-hr 
oxidized IgG1A 
T5 + + + 
R18  + + 
R24  + + 
T69  + + 
T74 + + + 
P80  + + 
T85 + + + 
T97  + + 
T109  + + 
T164 + + + 
T172  + + 
T180   + 
P204   + 
T206  + + 
Heavy Chain residues 
(position no.) 
   
R19   + 
T30 + + + 
T57  + + 
T98  + + 
T114 + + + 
T120  + + 
T135  + + 
T155 + + + 
K205   + 
K214   + 
T225 + + + 
T256  + + 
P271   + 
K290 + + + 
P329   + 
 



































Tryptic map of unstressed IgG1A
(non-GRT)





Figure 11. LC-MS base peak chromatograms of (A) Regular (non-GRT treated) tryptic maps of 
unstressed and 16-hour oxidized IgG1A. Peptide peaks either disappeared or became very small 




































Thermolysin map of unstressed IgG1A
(non-GRT)






Figure 11. LC-MS base peak chromatograms of (B) Regular (non-GRT treated) thermolysin 
maps of unstressed and 16-hour oxidized IgG1A. Peptide peaks either disappeared or became 

































Tryptic map of unstressed IgG1A
(GRT)





Figure 11. LC-MS base peak chromatograms of (C) GRT-derivatized tryptic maps of unstressed 
and 16-hour oxidized IgG1A. Peptide peaks either disappeared or became very small in the 































Thermolysin map of unstressed IgG1A
(GRT)




Figure 11. LC-MS base peak chromatograms of (D) GRT-derivatized thermolysin maps of 
unstressed and 16-hour oxidized IgG1A. Peptide peaks either disappeared or became very small 











             From the carbonylation sites identified on the unstressed, 2-hour, and 16-hour oxidized 
IgG1A, it was noticed that certain carbonylation sites were only identified on the 16-hour 
oxidized sample. It is unclear if all the identified target amino acid sites are equally susceptible 
to MCO-induced carbonylation. Further analysis by quantitative measurement in a site-specific 
manner will be very helpful to better understand the differences among various carbonylation 
sites. It should be noted, however, that relative quantitation by extracted ion chromatography in 
this approach will likely result in over-estimation of site-specific carbonylation levels due to the 
enhanced ionization efficiency of GRT-derived peptides.  For more accurate quantitation, stable 
isotope-labeled peptide standards may be required, and will be explored in the future studies.     
             Distribution of Carbonylation Sites on Three Highly Similar IgG1s. The distribution 
of carbonylation sites within the molecular structure of proteins is an interesting topic for further 
investigation.
(37, 38)
 An interesting example is that carbonylation sites on human serum albumin 
(HSA) are clustered while carbonylation sites on bovine serum albumin (BSA) are dispersed,
(37)
 
even though HSA and BSA share 75% sequence similarity. To further demonstrate the utility of 
this approach and to investigate if there are any common carbonylation sites on IgG1s, the 
oxidative carbonylation sites on three IgG1s sharing 91% sequence similarity were characterized. 
The oxidative carbonylation sites identified on the 16-hour oxidized IgG1B and IgG1C are 
summarized in Table 2. Of all the carbonylation sites identified, only 14 sites are common 
among all three IgG1s (highlighted in bold in Table 2). When the 14 common carbonylation sites 
were mapped to a crystal structure of full-length IgG1 (PDB entry 1HZH) antibody (Figure 12), 
it was found that all of these common sites are located on the surface and accessible to solvent. It 
should be interesting for future work to look for any patterns or structural motifs that might 




















Figure 12. Common carbonylation sites on oxidized IgG1A, IgG1B, and IgG1C displayed on a 
crystal structure of a full-length IgG1 (PD entry 1HZH) antibody in a surface representation 
using PyMOL software. Heavy chain is colored in blue and light chain is colored in orange. The 











           Metal catalyzed oxidative carbonylation forms a type of post-translational modification 
found in therapeutic proteins. Very little is known about this product variant, especially for mAb 
products. In this report, a novel analytical method that combines derivatization with GRT, 
peptide mapping with high resolution mass spectrometry, and database searching for high-
confidence identification of specific carbonylation sites on mAbs is demonstrated. This method 
effectively addresses a significant analytical challenge for the biotechnology industry for 
extended characterization of oxidative carbonylation. Compared with many existing analytical 
methodologies, this method has a key advantage of identifying carbonylation sites without using 
any affinity enrichment or fractionation steps. Two favorable features of the method were 
thought to enable such identification. First, the “charge-tagging” derivatization with GRT 
introduces a positive charge to the oxidation sites and provides enhanced ionization efficiency. 
Second, the high quality of CID MS
2
 spectra of GRT-derivatized peptides allows identification 
of carbonylation sites by database search with ease. Additionally, a simple data filtering process 
was incorporated to reduce false positive identifications, which provides a high degree of 
confidence in the assignment of carbonylation sites. Overall, this method is highly sensitive and 
effective as demonstrated by identification of specific carbonylation sites on both unstressed and 
oxidized mAb drug bulk substances.  
          To the best of my knowledge, this is the first report of comprehensive identification of 
oxidative carbonylation sites on recombinant monoclonal antibodies. This method is a valuable 
tool for the extended characterization of carbonylated product variants on mAbs and potentially 
other protein pharmaceuticals. Furthermore, this method may be also relevant in the case that 




affect safety or efficacy of a mAb, where examination of this variant on different lots may be 
necessary. Finally, it will be interesting for future studies to investigate the impact of oxidative 
carbonylation on biological functions of mAbs, although it can be difficult to tease out the 
specific effect of oxidative carbonylation from that of other concurrent modifications, such as 
regular methionine/tryptophan oxidations, induced by MCO. Nevertheless, application of this 
method in future studies will greatly enhance the understanding of this product quality attribute 



















                  For future studies, I would like to focus on the following three major areas: the 
degradation mechanism/factors that dictate the specificity and the extent of oxidative 
carbonylation on monoclonal antibodies, the effect of oxidative carbonylatio on the physical 
stability of mAbs, and the chemical consequence of the induced carbonyl groups on mAbs 
during long term storage and during in vitro incubation in plasma.  
                   The mechanism of oxidative carbonylation will be studied by stressing monoclonal 
antibodies under various oxidation conditions, including different types of metal ions (copper 
and iron), different concentrations of the metal ions and hydrogen peroxide, different pHs, 
different buffers/salts/surfactants (PS20, PS80, and Poloxmar), and different temperatures. 
Subsequently, these oxidized mAbs will be characterized for the total carbonylation levels and 
the site-specific carbonylation to address these questions: 1. Are metal ions are required for the 
carbonylation reaction? 2. Do copper and iron ions have different selectivity for the generation of 
the site-specific carbonylation? 3. Is there any antibody structure/sequence motif for the 
oxidative carbonylation? 4. Does carbonylation propensity depend on the presence of a 
neighboring carbonylation site or an adjacent metal binding site? 5. What factors promote or 
hinder oxidative carbonylation? 6. What are the predominant elements in the oxidation 
conditions that influence the extent of protein carboxylation? The answers to the above questions 
will provide valuable information to help design future mAbs with increased chemical stability 
against oxidative carbonylation. In addition, it will be extremely helpful to the development of 
the cell culture process or formulations that could minimize oxidative carbonylation during the 




              The effect of oxidative carbonylation on the physical stability of monoclonal antibodies 
is another important topic for future studies. This effect can be studied from multiple aspects. 
One experiment could be performed to measure the melting temperatures (Tm) and the heat 
capacities of carbonylated mAbs by differential scanning calorimetry (DSC). The DSC 
experiment, in combination with the site-specific carbonylation information, will be useful to 
assess the impact of carbonylation on mAb structural stability. In additional, this study could 
potentially identify the link/correlation (if exists) between site-specific carbonylation and the 
unfolding of the various domains in Fab and Fc. Other experiments using the conventional 
biophysical tools, such as 1-anilino-8-naphthalene sulfonate (ANS) binding fluorescence to 
probe the surface hydrophobicity, far- and near- UV circular dichroism to probe the impact on 
secondary and tertiary structure, can be helpful to provide further understanding of the impact of 
carbonylation on mAb physical stability, although proper controls should be introduced in these 
experiments to tease out the effects from other oxidative products (such as tryptophan and 
methionine oxidation) that are often co-generated by metal-catalyzed oxidation. 
            An intriguing hypothesis on the effect of oxidative carbonylation on the physical stability 
of mAbs is that oxidative carbonylation increases mAb aggregation propensity due to the 
increased protein hydrophobicity with carbonylation.
(23)
 It will be particularly interesting to 
investigate this hypothesis by studying the aggregation rates of carbonylated mAbs under 
accelerated thermal stress conditions, such as at 40 ºC, for 1, 2, and 4 weeks, where the size 
profiles can be monitored by size exclusion chromatography (SEC) and capillary electrophoresis 
sodium dodecyl sulfate (CE-SDS) analysis at each time point. Furthermore, assuming that 
oxidative carbonylation does drive aggregation, one would expect that certain carbonylation 




experiment, while the level of the corresponding carbonylation species will likely decrease in the 
main peak fractions. One experiment can be performed to compare the levels at each 
carbonylation sites for the main peak fraction and the aggregate fractions using the carbonylation 
peptide mapping method, which can provide a detailed picture at site-specific level which 
carbonylation residues may be involved in driving the aggregation.  
                 The chemical consequence (or the chemical instability) of the carbonyl groups on 
mAbs during storage should be investigated as well in future studies. The aldehyde groups may 
be susceptible to two chemical pathways: further oxidation to form carboxylic acid and 
formation of Schiff base with primary amines. For the first chemical pathway, the further 
oxidation product from the first pathway should be relatively easy to identify by peptide mapping 
analysis. However, the question is how stable are these aldehyde groups against further oxidation 
during storage and what factors influence the extent of the further oxidation to carboxylic acid. 
In addition, since formation of these carboxylic acids makes the mAb molecule more acidic 
(lower pIs) and more hydrophilic, how would that affect the physical stability of mAbs? For the 
second chemical pathway, the further degradation products from the second pathway are the 
intra- and inter- crosslinks between the aldehyde and lysine side chains and the n-terminal amino 
groups, particularly at higher pHs. Identification of these crosslinks may be challenging and 
require the use of some advanced analytical methodology. Nevertheless, this study will be 
necessary to help assess if these crosslinks do happen during manufacturing and storage, since 
crosslinks may lead to formation of aggregates, which poses an immunogenicity concern for 
mAbs products. 
                The physiochemical consequence of the carbonyl groups on mAbs under in vivo 




condition, since the in vivo environment (plasma) contains various proteins/enzymes and other 
biomolecules. As shown in the biological systems, intracellular, mildly carbonylated proteins are 
targeted for turn-over by enzymatic proteolysis, while extensively carbonylated proteins may 
escape proteolysis by forming high molecular weight species.
(13)
 In addition, there is a thiol-
dependent decarbonylation mechanism that cells use to process the carbonylated proteins.
(57)
 In 
the extracellular compartment (plasma), does the similar decarbonylation/proteolysis mechanism 
exist? If these mechanisms do exist, would they make carbonylation a less concerning quality 
attribute for mAb products? Answering these questions will be particularly important to 
assessing oxidative carbonylation as a critical quality attribute for mAb products, which typically 
have a half-life of several weeks in blood after being administrated. 
               One experiment will be performed to compare the physiochemical consequence of 
carbonylated mAbs incubated in rat plasma and in PBS at 37 °C for 0, 1, 2, 4, 6, and 10 days. At 
each time point, the mAb samples will be purified using anti-human IgG Fc IgGselect column 
using the experimental conditions described in Yin et al.’s paper.
(58)
 These purified mAb samples 
will then be analyzed for their total carbonylation levels and size heterogeneity profiles, which 
can reveal if the enzymatic proteolysis or the thiol-dependent decarbonylation mechanism also 
exists in the plasma. In addition, another specific aim of this study is to understand if significant 
amount of crosslinks may be formed between the carbonylated mAbs and the plasma proteins 
(via the Schiff-base chemistry), since these cross-linked protein complex can also be an 
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